Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03733561 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro

A Phase 1 study of Parkinson Disease, sponsored by Luye Pharma Group.

Completed
Registry status
Phase 1
Development phase
40
Enrollment target
1
Study location

NCT03733561 is a Phase 1 study of Parkinson Disease that has completed, run by Luye Pharma Group. The registered enrollment target is 40 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03733561, a Phase 1 study of Parkinson Disease, has completed, sponsored by Luye Pharma Group.

COMPLETED
Registry status
Phase 1
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

Phase 1, single center study to assess pharmacokinetic profiles of rotigotine after single dose of LY03003 and daily patch application of Neupro in Healthy Volunteers

Conditions Studied

Parkinson Disease

Interventions

  • DRUG LY03003
  • DRUG Neupro 4Mg/24Hr Transdermal Patch

Study Locations (1)

Maryland

  • Pharmaron CPC, Inc. - Baltimore

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2018-11-09
Est. Completion 2018-12-23
Phase Phase 1

Sponsor

Luye Pharma Group

22 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03733561

The ClinicalTrials.gov registry entry for NCT03733561 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The listed sponsor is Luye Pharma Group, which has 22 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which LY03003 is the first listed.

NCT03733561 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT03733561 about?

NCT03733561 is a clinical study titled "A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro". Phase 1, single center study to assess pharmacokinetic profiles of rotigotine after single dose of LY03003 and daily patch application of Neupro in Healthy Volunteers

What is the current status of trial NCT03733561?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2018-11-09. Estimated completion is 2018-12-23.

What conditions does trial NCT03733561 study?

This clinical trial studies the following conditions: Parkinson Disease.

What interventions are being tested in trial NCT03733561?

The interventions under investigation include: LY03003 (DRUG), Neupro 4Mg/24Hr Transdermal Patch (DRUG).

Who is sponsoring clinical trial NCT03733561?

This trial is sponsored by Luye Pharma Group, which has 22 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03733561 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Parkinson Disease

All registered trials for this condition

Maryland

All trials with a study site in Maryland

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.